잠시만 기다려 주세요. 로딩중입니다.

Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers

Journal of Korean Medical Science 2021년 36권 15호 p.110 ~ 110
송준영, 정희진, 김성란, 이승은, 김수현, 노지윤, 윤영경, 최원석, 박대원, 손장욱, 김우주, 김민자,
소속 상세정보
송준영 ( Song Joon-Young ) - Korea University College of Medicine Korea University Guro Hospital Department of Internal Medicine
정희진 ( Cheong Hee-Jin ) - Korea University College of Medicine Korea University Guro Hospital Department of Internal Medicine
김성란 ( Kim Sung-Ran ) - Korea University Guro Hospital Department of Infection Control
이승은 ( Lee Sung-Eun ) - Korea University Anam Hospital Department of Hospital Infection Control
김수현 ( Kim Su-Hyun ) - Korea University Ansan Hospital Department of Hospital Infection Control
노지윤 ( Noh Ji-Yun ) - Korea University College of Medicine Korea University Guro Hospital Department of Internal Medicine
윤영경 ( Yoon Young-Kyung ) - Korea University College of Medicine Korea University Anam Hospital Department of Internal Medicine
최원석 ( Choi Won-Suk ) - Korea University College of Medicine Korea University Ansan Hospital Department of Internal Medicine
박대원 ( Park Dae-Won ) - Korea University College of Medicine Korea University Ansan Hospital Department of Internal Medicine
손장욱 ( Sohn Jang-Wook ) - Korea University Anam Hospital Department of Hospital Infection Control
김우주 ( Kim Woo-Joo ) - Korea University College of Medicine Korea University Guro Hospital Department of Internal Medicine
김민자 ( Kim Min-Ja ) - Korea University College of Medicine Korea University Anam Hospital Department of Internal Medicine

Abstract


Hospital-based surveillance for adverse events was conducted on healthcare workers after they received the first dose of coronavirus disease 2019 (COVID-19) vaccine. Among the two new platform vaccines (messenger RNA- and adenoviral vector-based vaccines), the rates of systemic adverse events were significantly higher among adenovirus-vectored vaccine recipients. Fatigue (87.6% vs. 53.8%), myalgia (80.8% vs. 50.0%), headache (72.0% vs. 28.8%), and fever (≥ 38.0°C, 38.7% vs. 0%) were the most common adverse events among adenovirus-vectored vaccine recipients, but most symptoms resolved within 2 days. Both types of COVID-19 vaccines were generally safe, and serious adverse events rarely occurred.

키워드

COVID-19; Vaccine; Safety; Adverse Event; Surveillance

원문 및 링크아웃 정보

 

등재저널 정보